Advertisement

Psoriatic Arthritis and Infection

  • Frank Barnett Vasey
  • Luis R. Espinoza
Chapter

Abstract

An infectious etiology for both psoriasis and psoriatic arthritis has long been suspected. Accumulated evidence supports a role for Gram-positive bacteria and other microorganism(s) including viral agents. Streptococci and HIV are among the leading triggering agents in combination with genetic and immune-related factors. Regarding the latter, cell-mediated and humoral-mediated mechanisms play an important role. More recently, microbiota has also been shown to participate in its pathogenesis. In this chapter, we focus on its genetics, immunology, and infectious basis. Much has been learned and much more remains.

Keywords

Streptococcal infection HIV Innate immunity Adaptive immunity Psoriasis Psoriatic arthritis IL-17 TNF-alpha NF-Kappa B Genetics 

References

  1. 1.
    Thrastardottir T, Thorvardur JL. Infections and the risk of psoriatic arthritis among psoriasis patients. Rheumatol Int. 2017;38:1385–97.CrossRefGoogle Scholar
  2. 2.
    O’Reilly DD, Rahman P. Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2014;5:873–85.Google Scholar
  3. 3.
    Stuart PE, Nair RP, Tsoi LC, et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015;97:816–36.CrossRefGoogle Scholar
  4. 4.
    Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.CrossRefGoogle Scholar
  5. 5.
    Romani N, Brunner PM, Stingl G. Changing views of the role of Langerhans cells. J Investig Dermatol. 2012;32:872–81.CrossRefGoogle Scholar
  6. 6.
    Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases potential mechanistic links between skin disease and co-morbid conditions. J Investig Dermatol. 2010;130:1785–96.CrossRefGoogle Scholar
  7. 7.
    Gladman DD. Psoriatic arthritis recent advances in pathogenesis and treatment. Rheum Dis Clin North Am. 1992;18:247–55.PubMedGoogle Scholar
  8. 8.
    Didri M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;4:286–92.Google Scholar
  9. 9.
    Nickoloff BJ, Borish B, Huang B, et al. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci. 2000;24:212–25.CrossRefGoogle Scholar
  10. 10.
    Kruithof E, Baeten D, DeRycke L. Synovial histopathology of psoriatic arthritis, both oligo and poly articular resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7:569–80.CrossRefGoogle Scholar
  11. 11.
    Espinoza LR, Vasey FB, Espinoza CG, et al. Vascular changes in psoriatic synovium. Arthritis Rheum. 1982;25:677–84.CrossRefGoogle Scholar
  12. 12.
    Fiocco U, Martini V, Accordi B, et al. Transcriptional network profile or synovial fluid T cells in psoriatic arthritis. Clin Rheumatol. 2015;34:1571–80.CrossRefGoogle Scholar
  13. 13.
    Abji F, Pollock RA, Liang K, et al. Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. Clin Exp Rheumatol. 2018;36(3):486–9.PubMedGoogle Scholar
  14. 14.
    Abdou AG, Hanout HM. Evaluation of Survivin and NF-Kappa B an immune histo chemical study. J Cutan Pathol. 2008;35:445–51.CrossRefGoogle Scholar
  15. 15.
    Vereecke L, Beyaert R, van Loo G. The ubiquitin-editing enzyme A 20 (TNF A 1P3) is a central regulator of immunopathology. Trends Immunol. 2009;30:383–91.CrossRefGoogle Scholar
  16. 16.
    Wang C, Wu L, Bulek K, et al. The psoriasis-associated DION variant of the Adaptor Act 1 with impaired regulation by the molecular chaperone hsp 90. Nat Immunol. 2013;14:72–81.CrossRefGoogle Scholar
  17. 17.
    Paine A, Ritchlin C. Bone remodeling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol. 2016;28:66–75.CrossRefGoogle Scholar
  18. 18.
    Laria A, Lurati A, Marrazza M, et al. The macrophages in rheumatic disease. J Inflamm Res. 2016;9:1–11.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Wenik MH, Santegoets K, van Bon L. Macrophage dysfunction in psoriatic arthritis. J Transl Med. 2011;9(Suppl 2):59.CrossRefGoogle Scholar
  20. 20.
    Norholm-Pederson A. Infections and psoriasis. Acta Derm Venereol. 1952;32:159–67.Google Scholar
  21. 21.
    Tervaert WCC, Esseveld H. A study of the incidence of Haemolytic streptococci in the throat of patients with psoriasis vulgaris with reference to their role in the pathogenesis of this disease. Dermatologica. 1970;140:282–90.CrossRefGoogle Scholar
  22. 22.
    Quimby SR, Markowitz H, Winkleman RK. Anti-deoxyribonuclease B titres in psoriasis. Acta Derm Venereol (Stockh). 1980;60:485–90.Google Scholar
  23. 23.
    Vasey FB, Deitz C, Fenske NA, et al. Possible involvement of Group A streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol. 1982;9:719–22.PubMedGoogle Scholar
  24. 24.
    Yocum DE, Allen JB, Wahl SM, et al. Inhibition by cyclosporin A of streptococcal cell wall induced arthritis and hepatic granulomas in rats. Arthritis Rheum. 1986;29:262–73.CrossRefGoogle Scholar
  25. 25.
    Stimpson SA, Lerch RA, Cleleand DR, et al. Effect of acetylation on the arthopathic activity of group A streptococcal peptido-polysaccharide fragments. Infect Immun. 1987;55:16–23.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Wang Q, Vasey FB, Mahfood JP, et al. V2 Regions of 16S Ribosomal RNA used as a molecular marker for species identification of streptococci in peripheral blood and synovial fluid from patients with psoriatic arthritis. Arthritis Rheum. 1999;42:2055–9.CrossRefGoogle Scholar
  27. 27.
    Munz OH, Sela S, Baker BS, et al. Evidence of bacteria in the blood of psoriasis patients. Arch Dermatol Res. 2010;302:495–8.CrossRefGoogle Scholar
  28. 28.
    Candia L, Marquez J, Hernandez C, et al. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis a pathogenic role for innate immunity. J Rheumatol. 2007;34:374–9.PubMedGoogle Scholar
  29. 29.
    Hall RP, Gerber LH, Lawley TG. IgA-containing immune complexes in patients with psoriatic arthritis. Clin Exp Rheumatol. 1984;2:221–5.PubMedGoogle Scholar
  30. 30.
    Espinoza LR, Berman A, Vasey FB, Cahalin C, Nelson R, Germain BF. Psoriatic arthritis and acquired immunodeficiency syndrome. Arthritis Rheum. 1988;31:1034–40.CrossRefGoogle Scholar
  31. 31.
    Njobuu P, McGill P. Psoriatic arthritis and human immunodeficiency virus infection in Zambia. J Rheumatol. 2000;27:1699–702.Google Scholar
  32. 32.
    Chen YJ, Ho HJ, Tseng CH, Lai ZL, Shieh JJ, Wu CY. Intestinal microbiota profiling in psoriatic patients. Exp Dermatol. 2018;27(12):1336–43.CrossRefGoogle Scholar
  33. 33.
    Giles E, Mortier C, Venken K, Debusschere K, Vereecke L, Elewaut D. The role of the microbiome in gut and joint inflammation in psoriatic arthritis and spondyloarthritis. J Rheumatol Suppl. 2018;94:36–9.Google Scholar
  34. 34.
    Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67:128–39.CrossRefGoogle Scholar
  35. 35.
    Scarpa R, Manguso F, D’Arienzo A, D’Armiento FP, Astarita C, Mazzacca G, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27:1241–6.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Frank Barnett Vasey
    • 1
  • Luis R. Espinoza
    • 2
  1. 1.Department of Internal Medicine, Division of RheumatologyUniversity of South Florida College of MedicineTampaUSA
  2. 2.LSU Health Sciences at New Orleans, Louisiana State UniversityNew OrleansUSA

Personalised recommendations